Company Overview

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases. The company operates primarily in the biopharmaceutical and biotechnology industries, with a strong emphasis on genetic medicine, monoclonal antibodies, and biologics. Regeneron’s core revenue drivers are its proprietary antibody-based therapies, developed using its internal research platforms and brought to market through a combination of wholly owned products and strategic collaborations.

Regeneron serves global healthcare markets, primarily addressing ophthalmology, immunology, oncology, cardiovascular disease, infectious diseases, and rare genetic disorders. Its competitive positioning is driven by its vertically integrated R&D model, long-term investment in genetics research, and proprietary platforms such as VelociSuite technologies. Founded in 1988, Regeneron evolved from a research-focused startup into a large-cap biotechnology leader through sustained internal innovation, selective partnerships, and successful commercialization of blockbuster therapies.

Business Operations

Regeneron operates through a single reportable segment focused on the discovery, development, manufacturing, and commercialization of biopharmaceutical products. Revenue is generated primarily from product sales and, to a lesser extent, collaboration revenues. Key commercial products include EYLEA (aflibercept) for retinal diseases, Dupixent (dupilumab) for multiple inflammatory conditions, and Libtayo (cemiplimab) for oncology indications, with Dupixent and Libtayo commercialized in collaboration with Sanofi in certain territories.

The company maintains extensive in-house capabilities, including research laboratories, clinical development, biologics manufacturing, and supply chain operations. Regeneron controls advanced antibody discovery and production technologies through its VelociSuite platform and operates large-scale manufacturing facilities in the United States and Europe. Its operations include multiple wholly owned subsidiaries supporting research, manufacturing, and international commercialization, alongside long-standing collaborative arrangements with major pharmaceutical partners.

Strategic Position & Investments

Regeneron’s strategy centers on sustained internal innovation, lifecycle expansion of existing products, and development of new therapies across multiple disease areas. Growth initiatives include advancing late-stage clinical programs in immunology, oncology, ophthalmology, and genetic medicines, as well as expanding indications for existing products. The company consistently reinvests a significant portion of revenue into research and development to maintain a deep and diversified pipeline.

Strategic investments include long-term collaborations rather than frequent large-scale acquisitions. Notable investments include Regeneron’s genetics research efforts through the Regeneron Genetics Center, which supports drug discovery using large-scale human genetic data. The company is also actively involved in emerging areas such as RNA-based therapeutics, bispecific antibodies, and next-generation biologics, leveraging internal platforms rather than external portfolio roll-ups.

Geographic Footprint

Regeneron is headquartered in North America, with its corporate headquarters located in Tarrytown, New York. The company has a significant operational presence across the United States, including major research and manufacturing facilities in New York and additional manufacturing capacity in other states. These domestic operations account for the majority of its research, development, and production activities.

Internationally, Regeneron maintains a growing footprint across Europe, Asia-Pacific, and other global markets through subsidiaries, partnerships, and distributor relationships. Commercial presence outside the United States is particularly strong in Europe, where products such as EYLEA and Dupixent are marketed directly or through collaborators, supporting Regeneron’s global revenue base and clinical development programs.

Leadership & Governance

Regeneron was co-founded by Leonard S. Schleifer, whose scientific background continues to influence the company’s research-driven culture. The leadership team emphasizes long-term value creation through scientific excellence, disciplined capital allocation, and maintaining control over core technologies and decision-making processes. Governance is structured to support independent research while balancing collaboration with global pharmaceutical partners.

Key executives include:

• Leonard S. Schleifer – President, Chief Executive Officer, and Co-Founder
• George D. Yancopoulos – Co-Founder, President of Research and Development, and Chief Scientific Officer
• Robert E. Landry – Executive Vice President, Finance and Chief Financial Officer
• Christopher R. Fenimore – Senior Vice President, General Counsel and Secretary
• Roy Vagelos – Chairman of the Board

The leadership team collectively drives Regeneron’s strategy of sustained innovation, deep scientific investment, and long-term independence in drug discovery and development.